Format

Send to

Choose Destination
See comment in PubMed Commons below
Therapie. 2011 Sep-Oct;66(5):377-81. doi: 10.2515/therapie/2011055. Epub 2011 Oct 27.

[Pharmacological management of inflammatory rheumatic conditions].

[Article in French]

Author information

  • 1Universite Victor Segalen, Bordeaux, France. bernard.bannwarth@u-bordeaux2.fr

Abstract

Inflammatory rheumatic disorders are related to different pathophysiological mechanisms and, hence, their therapeutic management varies according to the underlying disease. Crystal-induced arthritis is characterized by its almost specific responsiveness to colchicine. Regarding ankylosing spondylitis, non steroidal anti-inflammatory drugs (NSAIDs) and TNF blockers are the cornerstones of pharmacological intervention whereas oral corticosteroids at conventional doses are of little value, if any. Conversely, corticosteroids are the drug of choice to treat polymyalgia rheumatica. Furthermore, low-dose corticosteroids were shown to be more effective than NSAIDs in patients with rheumatoid arthritis (RA). However, the main goal being to achieve remission, disease-modifying antirheumatic drugs, either synthetic, especially methotrexate, and/or biologic, such as TNF inhibitors, have a major role in the management of RA. Finally, enhanced understanding of molecular pathogenesis of inflammatory disorders may help to find out how to best target available drugs to right individuals in the future.

© 2011 Société Française de Pharmacologie et de Thérapeutique.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for EDP Sciences
    Loading ...
    Write to the Help Desk